On October 27, 2023 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, reported that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin in patients with peritoneal carcinomatosis from colorectal cancer (Press release, Oncoinvent, OCT 27, 2023, https://www.oncoinvent.com/press-release/oncoinvent-announces-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-radspherin-in-colorectal-cancer-patients/ [SID1234636416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to announce the IND clearance for Radspherin for colorectal cancer patients following the promising indications of safety and efficacy from the RAD-18-002 Phase 1/2a clinical trial, " said Anders Månsson, Chief Executive Officer of Oncoinvent. "This is an important corporate milestone for Oncoinvent, allowing us to clinically advance Radspherin and expand to the U.S. landscape. Today’s announcement, in conjunction with the positive clinical data supporting Radspherin, continues to reinforce our belief in its transformative potential, and we look forward to advancing its clinical development."

In the ongoing phase 1/2a clinical trials with Radspherin, all dose levels have to date been well tolerated and 7MBq was selected as the recommended dose. Oncoinvent recently presented preliminary 18-month safety and efficacy data from the ongoing RAD-18-002 study in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies (PSOGI). At 18 months, none of the 12 patients who received the recommended dose of 7 MBq experienced peritoneal recurrences.

Only 2.6% of all adverse events reported were considered to be related to Radspherin, all of which were grade 1-2.

The planned trial, for which we have now received FDA clearance, is a randomized controlled phase 2b trial, assessing efficacy and safety of Radspherin in patients with peritoneal carcinomatosis from colorectal carcinoma following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The primary objective for the trial, planned to start in Q2 of 2024, is to compare progression-free survival (PFS) between patients following CRS and HIPEC and Radspherin versus CRS and HIPEC.